The Technical Analyst
United Health Products, [UEEC]
Exchange: PNK Industry: Medical Instruments & Supplies
United Health Products, Price, Forecast, Insider, Ratings, Fundamentals & Signals
4.29% $0.180
America/New_York / 3 mai 2024 @ 13:52
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 44.41 mill |
| EPS: | -0.0100 |
| P/E: | -17.99 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 246.83 mill |
| Avg Daily Volume: | 0.157 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -17.99 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -17.99 | industry: PE -6.22 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0029 (-101.60%) $-0.183 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.157 - 0.203 ( +/- 12.78%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-05-12 | Thom Brian David | Sell | 300 000 | Common shares |
| 2023-04-17 | Thom Brian David | Buy | 309 375 | Common Shares |
| 2022-12-31 | Heaton Kristofer | Buy | 0 | |
| 2023-01-13 | Thom Brian David | Buy | 225 000 | Common Shares |
| 2022-12-31 | Thom Brian David | Buy | 0 |
| INSIDER POWER |
|---|
| 23.87 |
| Last 87 transactions |
| Buy: 55 072 338 | Sell: 23 372 521 |
Forecast:
15:32 - $0.182
Live Trading Signals (every 1 min)
Forecast
1: 14:02 - $0.180
Forecast 2: 14:52 - $0.176
Forecast 3: 15:32 - $0.182
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.180 (4.29% ) |
| Volume | 0.275 mill |
| Avg. Vol. | 0.157 mill |
| % of Avg. Vol | 174.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For UEEC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
UEEC
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers HemoStyp hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, assisted living and nursing homes, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. United Health Products, Inc. was incorporated in 1997 and is headquartered in Henderson, Nevada.
Latest Press Releases
2024-03-21 08:37:00 - Press Release
United Health Products Submits Full Fda Pma Application
Mount laurel, nj, march 21, 2024 (globe newswire) -- via newmediawire -- united health products, inc. (otcpk: ueec) today provided an update on the company's fda premarket approval application process.
2024-01-19 08:32:00 - Press Release
United Health Products Reports On Fda Application Status
Mesquite, nv, jan. 19, 2024 (globe newswire) -- via newmediawire – united health products (ueec) reports today on the receipt and review of final reports on product sterilization and stability testing for its hemostatic gauze. as previously disclosed, uhp has been working with external packaging and sterilization service providers to complete various required tests for its premarket approval application. the reported data received this week on the efficacy of the proposed radiation sterilization protocol were well within acceptable bioburden levels for class iii products. uhp will now compile these data and proceed with final drafting of the pma documentation to be submitted via the estar platform for fda and health canada review.
2023-10-03 16:30:00 - Press Release
United Health Products Reports On Fda Application Status
Mesquite, nv, oct. 03, 2023 (globe newswire) -- via newmediawire - united health products, inc. (otcpk: ueec) today provided an update on the company's fda premarket approval application process.
2023-08-04 08:29:00 - Press Release
United Health Products Reports On Product Testing For Fda Application
Mesquite, nv, aug. 04, 2023 (globe newswire) -- via newmediawire – united health products, inc. (otcpk: ueec) today provided an update on the company's fda premarket approval application process.
2021-06-28 15:30:00 - Press Release
United Health Products Provides Corporate Update And Announces Equity Financing
Henderson, nv / accesswire / june 28, 2021 / united health products, inc. (otcpk:ueec), ('uhp'), developer, manufacturer and marketer of hemostyp, a patented neutralized oxidized regenerated cellulose hemostatic agent, today provided a corporate update on its current product development and commercialization activities. in anticipation of a successful outcome to its class iii pre-market approval (pma) application, the uhp team is pursuing several initiatives that will maximize the addressable market for its hemostyp gauze and additional formats which, if approved by the fda, will allow uhp to offer a full suite of class iii hemostatic formats to the human surgical market.
Latest News
2023-06-04 12:49:31 - Forbes
Dow Stocks To Trade In June
2022-12-04 12:00:04 - Forbes
Dow Stocks To Trade In December
2021-12-05 17:07:17 - Forbes
Stocks To Trade In December
2021-06-28 15:30:00 - Accesswire
United Health Products Provides Corporate Update and Announces Equity Financing
HENDERSON, NV / ACCESSWIRE / June 28, 2021 / United Health Products, Inc. (OTCPK:UEEC), ('UHP'), developer, manufacturer and marketer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose hemostatic agent, today provided a corporate update on its current product development and commercialization activities. In anticipation of a successful outcome to its Class III Pre-market Approval (PMA) application, the UHP team is pursuing several initiatives that will maximize the addressable market for its HemoStyp gauze and additional formats which, if approved by the FDA, will allow UHP to offer a full suite of Class III hemostatic formats to the human surgical market.
2021-05-05 08:10:00 - Business Wire
United Health Products' HemoStyp® Gauze Advances to FDA Substantive Review
HENDERSON, Nev.--(BUSINESS WIRE)--United Health Products, Inc. (OTCPK: UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose hemostatic agent, received notification this week from the Food & Drug Administration (FDA) that, following the resubmission of its application for Pre-market Approval for HemoStyp gauze on April 6th, the FDA has now accepted for review and commenced its Substantive Review of the appli